The estimated Net Worth of George A. Iii Samuel is at least $8.37 mil dollars as of 11 February 2024. Mr Samuel owns over 6,076 units of Lineage Cell Therapeutics Inc stock worth over $8,370 and over the last 3 years he sold LCTX stock worth over $0.
Mr has made over 2 trades of the Lineage Cell Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 6,076 units of LCTX stock worth $5,257 on 11 February 2024.
The largest trade he's ever made was exercising 6,076 units of Lineage Cell Therapeutics Inc stock on 11 February 2024 worth over $5,257. On average, Mr trades about 1,736 units every 52 days since 2021. As of 11 February 2024 he still owns at least 9,674 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Mr Samuel stock trades at the bottom of the page.
George A. Samuel III, J.D. is the Gen. Counsel & Company Sec. at Lineage Cell Therapeutics Inc.
George's mailing address filed with the SEC is 2173 SALK AVENUE, SUITE 200, , CARLSBAD, CA, 92008.
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley y Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include: